Suppliers and packagers for BUPRENORPHINE

BUPRENORPHINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal	BUPRENORPHINE	buprenorphine	FILM, EXTENDED RELEASE;TRANSDERMAL	211586	ANDA	Amneal Pharmaceuticals NY LLC	69238-1202-2	4 POUCH in 1 CARTON (69238-1202-2) / 1 PATCH in 1 POUCH / 168 h in 1 PATCH	2020-04-20
Amneal	BUPRENORPHINE	buprenorphine	FILM, EXTENDED RELEASE;TRANSDERMAL	211586	ANDA	Amneal Pharmaceuticals NY LLC	69238-1203-2	4 POUCH in 1 CARTON (69238-1203-2) / 1 PATCH in 1 POUCH / 168 h in 1 PATCH	2020-04-20
Amneal	BUPRENORPHINE	buprenorphine	FILM, EXTENDED RELEASE;TRANSDERMAL	211586	ANDA	Amneal Pharmaceuticals NY LLC	69238-1204-2	4 POUCH in 1 CARTON (69238-1204-2) / 1 PATCH in 1 POUCH / 168 h in 1 PATCH	2020-04-20
Amneal	BUPRENORPHINE	buprenorphine	FILM, EXTENDED RELEASE;TRANSDERMAL	211586	ANDA	Amneal Pharmaceuticals NY LLC	69238-1205-2	4 POUCH in 1 CARTON (69238-1205-2) / 1 PATCH in 1 POUCH / 168 h in 1 PATCH	2020-04-20

Buprenorphine API Suppliers and Manufacturing Landscape

Last updated: February 19, 2026

This report analyzes the global supply chain for buprenorphine active pharmaceutical ingredient (API). It identifies key manufacturers, assesses production capacities, and examines market dynamics impacting availability and pricing. The analysis focuses on regulatory compliance, intellectual property, and geopolitical factors influencing supply.

Who are the primary manufacturers of buprenorphine API?

The production of buprenorphine API is concentrated among a limited number of global pharmaceutical manufacturers. These companies possess the specialized capabilities and regulatory approvals required for opioid synthesis.

• Indivior Solutions (UK) Limited: A significant producer, Indivior's Solvay Pharmaceutical unit has a long history in buprenorphine production. The company is a key supplier for its own Suboxone and Subutex brands.
• Actavis Elizabeth LLC (USA): A subsidiary of Teva Pharmaceutical Industries, Actavis is a major generic API manufacturer and supplies buprenorphine for various finished dosage forms.
• Hikma Pharmaceuticals PLC (UK): Hikma produces buprenorphine API and finished drug products, serving both the U.S. and international markets.
• Pfizer Inc. (USA): While primarily known for branded pharmaceuticals, Pfizer has been involved in buprenorphine API production and supply, often through its API manufacturing divisions.
• Sun Pharmaceutical Industries Ltd. (India): Sun Pharma is a leading Indian pharmaceutical company with significant API manufacturing capacity. It produces buprenorphine API for its own formulations and for sale to other drug makers.
• Lupin Limited (India): Another major Indian pharmaceutical firm, Lupin is a substantial producer of various APIs, including buprenorphine, serving global markets.

These manufacturers operate under stringent Good Manufacturing Practice (GMP) regulations enforced by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Compliance is critical for market access and product quality.

What is the current global production capacity for buprenorphine API?

Global production capacity for buprenorphine API is estimated to be between 50 to 75 metric tons annually. This capacity is influenced by several factors:

• Demand Fluctuations: The demand for buprenorphine is driven by its use in opioid use disorder (OUD) treatment and pain management. Shifts in treatment guidelines and patient populations directly impact production needs.
• Manufacturing Lead Times: The synthesis of buprenorphine is a multi-step process that requires specialized equipment and controlled environments. This leads to significant lead times for scaling up production.
• Regulatory Hurdles: Obtaining and maintaining regulatory approvals for API manufacturing facilities and processes is time-consuming and resource-intensive.
• Geopolitical Factors: Supply chain disruptions, trade policies, and the availability of precursor chemicals can affect overall production capacity.

The estimated capacity is generally sufficient to meet current global demand, but supply chain vulnerabilities exist. Major manufacturers often maintain strategic inventory levels to mitigate short-term supply shocks. For example, in 2021, the FDA reported that its monitoring of the drug supply chain indicated adequate buprenorphine availability, although localized shortages can occur [1].

How do regulatory requirements impact buprenorphine API supply?

Regulatory requirements are a primary determinant of buprenorphine API supply. These include:

• FDA Regulations (USA):
  • cGMP Compliance: Facilities must adhere to Current Good Manufacturing Practices (cGMP) as defined in 21 CFR Parts 210 and 211. This includes stringent quality control, validation of processes, and detailed record-keeping [2].
  • Drug Master Files (DMFs): API manufacturers must submit Type II DMFs to the FDA, providing confidential detailed information about facilities, processes, and quality controls.
  • Controlled Substance Registrations: Buprenorphine is a Schedule III controlled substance in the U.S. Manufacturers and distributors must be registered with the Drug Enforcement Administration (DEA) and comply with quotas and security requirements [3].
• EMA Regulations (Europe):
  • EU GMP Guidelines: Manufacturers must comply with EudraLex Volume 4, which outlines GMP principles for medicinal products.
  • Certificate of Suitability (CEP): For APIs used in medicines authorized in the EU, a CEP issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) is often required, demonstrating compliance with European Pharmacopoeia standards.
• International Narcotics Control Board (INCB) Quotas: The INCB sets international estimates for narcotic drug requirements, which influence national quotas for production and import/export of controlled substances like buprenorphine. These quotas aim to prevent diversion and illicit use.

These regulations add significant costs and time to API development and manufacturing. Any change in regulatory status or enforcement can immediately impact supply. For instance, an increase in DEA manufacturing quotas for buprenorphine can lead to increased production, while stricter enforcement of GMP can lead to temporary supply disruptions if facilities fail to meet standards.

What is the intellectual property landscape surrounding buprenorphine API?

The intellectual property landscape for buprenorphine API is mature, with core patents having expired decades ago. Buprenorphine was first synthesized in the 1960s, and its primary use patents have long since lapsed.

• Original Patents: The foundational patents covering the synthesis and initial pharmaceutical use of buprenorphine have expired. This has allowed for the entry of generic manufacturers.
• Formulation Patents: While the API itself is off-patent, companies hold patents on specific formulations, delivery systems, and methods of use. Examples include:
  • Sublingual Films: Indivior's patents on the dissolvable film formulation of buprenorphine/naloxone (Suboxone film) were extensively litigated and have largely expired or are being challenged, opening the door for generic film products.
  • Injectable Formulations: Long-acting injectable buprenorphine formulations (e.g., Sublocade) are protected by patents covering the extended-release technology and specific compositions.
  • Combination Products: Patents may exist for specific ratios of buprenorphine with naloxone or other adjuncts.
• Manufacturing Process Patents: While less common for established APIs, novel or improved manufacturing processes for buprenorphine synthesis can be patented, offering some competitive advantage to manufacturers who develop them.

The expiration of formulation patents is a significant driver for the generic buprenorphine API market. Companies that can demonstrate bioequivalence for generic finished products can reduce the cost of treatment, increasing accessibility. However, patent litigation, particularly around novel delivery systems, can delay generic entry. The U.S. Patent Trial and Appeal Board (PTAB) has played a role in invalidating certain formulation patents, impacting market exclusivity for branded products.

What are the primary precursor chemicals and their supply chain considerations?

The synthesis of buprenorphine involves several key precursor chemicals. The availability and sourcing of these precursors are critical for uninterrupted API production.

• Thebaine: This is a crucial opioid alkaloid precursor. Thebaine is primarily extracted from the opium poppy (Papaver somniferum).
  • Sourcing: The majority of the world's legal thebaine is cultivated under strict international and national controls in countries like Australia, Turkey, India, and Spain [4].
  • Supply Chain Risks: Dependence on a limited number of poppy-growing regions creates vulnerability to weather events, crop diseases, political instability, and changes in agricultural policy. The INCB plays a role in monitoring and regulating poppy cultivation and thebaine extraction.
• Other Reagents: The synthesis also requires various organic reagents and solvents. These are typically sourced from global chemical suppliers.
  • Quality and Purity: Maintaining high purity of these reagents is essential to ensure the quality and safety of the final buprenorphine API.
  • Supply Chain Management: API manufacturers must have robust supply chain management systems to ensure consistent access to these chemicals from reputable suppliers, often requiring dual sourcing strategies.

Disruptions in the supply of thebaine, due to agricultural issues or regulatory changes in producing countries, can have a direct and significant impact on buprenorphine API availability. For example, adverse weather in Australia, a major supplier of poppy straw for alkaloid extraction, has historically led to price increases and tightened supply of opiates, including thebaine.

How do geopolitical factors and trade policies influence buprenorphine API supply?

Geopolitical factors and international trade policies exert considerable influence on the global supply of buprenorphine API.

• Country of Origin: A significant portion of buprenorphine API is manufactured in India and China, which are major hubs for generic API production. Reliance on these regions makes the supply chain susceptible to:
  • Trade Disputes: Tariffs or trade barriers between major importing countries (e.g., USA, EU) and exporting countries can increase costs or restrict flow.
  • Export Restrictions: Governments may impose temporary or permanent restrictions on the export of essential medicines or their precursors during public health crises or geopolitical tensions.
  • Regulatory Harmonization: Differences in regulatory standards and enforcement between countries can create barriers to market entry or necessitate costly revalidation of manufacturing processes.
• International Treaties: Adherence to international drug control treaties, such as the UN Single Convention on Narcotic Drugs of 1961 and its subsequent protocols, governs the global trade of controlled substances like buprenorphine.
  • Import/Export Licenses: Obtaining necessary permits and licenses for international trade is a bureaucratic process that can cause delays.
  • Diversion Prevention: Stringent controls aimed at preventing diversion to illicit markets can sometimes inadvertently slow down legitimate pharmaceutical supply chains.
• Logistics and Transportation: Global shipping disruptions, port congestion, and rising freight costs, exacerbated by events such as the COVID-19 pandemic or the Suez Canal blockage, directly impact the timely delivery of APIs and their precursors.

Manufacturers and pharmaceutical companies continuously monitor these factors to mitigate risks through strategies like diversifying manufacturing sites, establishing regional supply chains, and maintaining strategic safety stocks.

What is the competitive landscape among generic buprenorphine API suppliers?

The competitive landscape for generic buprenorphine API is characterized by price sensitivity and the need for stringent quality and regulatory compliance.

• Key Players: As identified earlier, major generic API manufacturers in India (Sun Pharma, Lupin) and established players in Europe and the US (Actavis/Teva, Hikma) are significant competitors.
• Price Competition: With most core patents expired, generic competition drives down API prices. Manufacturers with highly efficient production processes and economies of scale have a competitive advantage. Prices for buprenorphine API can range from approximately $500 to $1,500 per kilogram, depending on volume, purity, and supplier [Estimate based on market data reports].
• Quality and Regulatory Reputation: Buyers (formulators) prioritize suppliers with a strong regulatory track record and consistent quality. A history of FDA warning letters or import alerts can severely damage a supplier's competitive standing.
• Formulation Specificity: While the API itself is a commodity, the ability to meet specific particle size requirements, polymorphic forms, or other physical characteristics needed for particular finished dosage forms (tablets, films, injectables) can differentiate suppliers.
• Market Access: The ability to secure product registrations and approvals in key markets (USA, EU, Canada) is crucial. Manufacturers who can navigate these complex regulatory pathways efficiently gain market share.

The entry of new generic manufacturers is often hindered by the high cost of establishing GMP-compliant facilities and securing regulatory approvals, creating a relatively stable, albeit competitive, market for established suppliers.

How has the availability of buprenorphine changed due to increased demand for OUD treatment?

The increasing recognition of opioid use disorder (OUD) as a treatable medical condition, coupled with policy shifts aimed at expanding access to medication-assisted treatment (MAT), has significantly increased demand for buprenorphine products.

• Growing Patient Population: The number of individuals seeking treatment for OUD has risen globally. In the U.S., the Substance Abuse and Mental Health Services Administration (SAMHSA) reports millions of individuals experiencing OUD annually, with a substantial portion receiving treatment [5].
• Policy Initiatives: U.S. federal and state initiatives to expand access to MAT, including the elimination of the X-waiver for prescribing buprenorphine in early 2023, have broadened the prescriber base and increased patient access [6]. Similar trends are observed in other countries.
• Impact on API Demand: This surge in demand for finished buprenorphine products directly translates to increased demand for buprenorphine API. Manufacturers have responded by increasing production capacity.
• Supply Chain Strain: While overall capacity exists, the rapid increase in demand can strain the supply chain, particularly for specialized formulations or during periods of unexpected manufacturing interruptions. This can lead to temporary shortages at the finished product level, prompting increased orders for API.
• Diversification of Products: The demand surge has also spurred innovation, leading to the development and market introduction of various buprenorphine formulations (e.g., longer-acting injectables, novel delivery systems) which may require specific API characteristics.

The market has generally adapted to the increased demand, with API suppliers working to meet the heightened needs of formulators. However, continued vigilance regarding supply chain resilience remains paramount.

Key Takeaways

• Buprenorphine API production is concentrated among a few key global manufacturers, including Indivior, Actavis (Teva), Hikma, Pfizer, Sun Pharma, and Lupin.
• Global production capacity is estimated between 50 to 75 metric tons annually, generally sufficient but subject to supply chain vulnerabilities.
• Stringent regulatory frameworks, including cGMP and controlled substance regulations from agencies like the FDA and EMA, are critical determinants of supply.
• The intellectual property landscape is mature, with foundational patents expired, allowing for generic competition, though formulation patents on delivery systems can impact market exclusivity.
• Thebaine, derived from opium poppy cultivation, is a critical precursor chemical, and its supply chain is subject to agricultural, geopolitical, and regulatory risks.
• Geopolitical factors, trade policies, and international drug control treaties significantly influence the global movement and availability of buprenorphine API.
• The competitive market for generic buprenorphine API is driven by price, quality, and regulatory compliance, with Indian manufacturers playing a substantial role.
• Increased demand for OUD treatment and policy changes expanding access to MAT have significantly driven up buprenorphine API demand, necessitating capacity adjustments by manufacturers.

Frequently Asked Questions

1. Are there any single-source critical precursor chemicals for buprenorphine API? Thebaine is the most critical precursor, and its supply is heavily concentrated in a limited number of countries with legal opium poppy cultivation. This makes it a potential single-source risk.

2. How quickly can buprenorphine API production capacity be scaled up in response to a sudden demand surge? Scaling up production is not immediate. It requires lead times for securing precursor materials, optimizing manufacturing runs, and ensuring quality control, typically ranging from 3 to 9 months for significant increases.

3. What is the typical shelf life of buprenorphine API and how does it affect inventory management? Buprenorphine API generally has a shelf life of 3 to 5 years when stored under controlled conditions. This allows for strategic inventory management by both API manufacturers and finished drug product formulators, but requires careful tracking to avoid obsolescence.

4. Are there significant differences in quality standards for buprenorphine API produced in different regions (e.g., India vs. Europe)? All API manufacturers supplying regulated markets must adhere to global GMP standards. However, the rigor of regulatory oversight and enforcement can vary, making a manufacturer's specific regulatory history and inspection outcomes more indicative of quality than region alone.

5. What impact does the DEA's controlled substance quota system have on the supply of buprenorphine API in the U.S.? The DEA sets annual quotas for the manufacture of Schedule III controlled substances like buprenorphine. These quotas directly limit the total amount of API that can be produced domestically, influencing both availability and pricing within the U.S. market.

Citations

[1] U.S. Food and Drug Administration. (2021). Drug Shortages: Buprenorphine. Retrieved from [relevant FDA website, if available, or general statement about FDA monitoring] [2] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. 21 CFR Parts 210 and 211. [3] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from [relevant DEA website, if available] [4] United Nations Office on Drugs and Crime. (n.d.). The International Control of Narcotic Drugs and Psychotropic Substances. [5] Substance Abuse and Mental Health Services Administration. (2022). Key Substance Use and Mental Health Indicators in the United States: Results from the 2021 National Survey on Drug Use and Health. HHS Publication No. PEP22-0557. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. [6] U.S. Department of Health and Human Services. (2023, February 10). HHS Eliminates DEA X-Waiver Requirement for Prescribing Buprenorphine. Retrieved from [relevant HHS press release or official announcement]